Published in Br J Cancer on September 28, 2010
Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med (2012) 44.56
Evolution and impact of subclonal mutations in chronic lymphocytic leukemia. Cell (2013) 9.24
Genomic architecture and evolution of clear cell renal cell carcinomas defined by multiregion sequencing. Nat Genet (2014) 5.74
Mutational analysis reveals the origin and therapy-driven evolution of recurrent glioma. Science (2013) 4.42
Decoding tumour phenotype by noninvasive imaging using a quantitative radiomics approach. Nat Commun (2014) 4.16
Intratumor heterogeneity: evolution through space and time. Cancer Res (2012) 3.45
Combinatorial drug therapy for cancer in the post-genomic era. Nat Biotechnol (2012) 3.10
Evolutionary dynamics of carcinogenesis and why targeted therapy does not work. Nat Rev Cancer (2012) 2.71
Cancer heterogeneity: implications for targeted therapeutics. Br J Cancer (2013) 2.56
Cancer chromosomal instability: therapeutic and diagnostic challenges. EMBO Rep (2012) 2.28
Insight into the heterogeneity of breast cancer through next-generation sequencing. J Clin Invest (2011) 1.99
Evolutionary medicine: its scope, interest and potential. Proc Biol Sci (2012) 1.94
SciClone: inferring clonal architecture and tracking the spatial and temporal patterns of tumor evolution. PLoS Comput Biol (2014) 1.88
Divergent clonal selection dominates medulloblastoma at recurrence. Nature (2016) 1.81
Clonal evolution enhances leukemia-propagating cell frequency in T cell acute lymphoblastic leukemia through Akt/mTORC1 pathway activation. Cancer Cell (2014) 1.79
Genomic and mutational profiling of ductal carcinomas in situ and matched adjacent invasive breast cancers reveals intra-tumour genetic heterogeneity and clonal selection. J Pathol (2012) 1.78
Exploiting evolutionary principles to prolong tumor control in preclinical models of breast cancer. Sci Transl Med (2016) 1.62
Plasticity of tumour and immune cells: a source of heterogeneity and a cause for therapy resistance? Nat Rev Cancer (2013) 1.61
Quantitative imaging in cancer evolution and ecology. Radiology (2013) 1.55
Sweat but no gain: inhibiting proliferation of multidrug resistant cancer cells with "ersatzdroges". Int J Cancer (2014) 1.44
From human genome to cancer genome: the first decade. Genome Res (2013) 1.42
Relationship of extreme chromosomal instability with long-term survival in a retrospective analysis of primary breast cancer. Cancer Epidemiol Biomarkers Prev (2011) 1.38
Building a personalized medicine infrastructure at a major cancer center. J Clin Oncol (2013) 1.36
High-throughput sequencing of T-cell receptors reveals a homogeneous repertoire of tumour-infiltrating lymphocytes in ovarian cancer. J Pathol (2013) 1.31
TrAp: a tree approach for fingerprinting subclonal tumor composition. Nucleic Acids Res (2013) 1.23
Clinical management of breast cancer heterogeneity. Nat Rev Clin Oncol (2015) 1.22
Life history trade-offs in cancer evolution. Nat Rev Cancer (2013) 1.16
Intra- and inter-tumor heterogeneity in a vemurafenib-resistant melanoma patient and derived xenografts. EMBO Mol Med (2015) 1.11
Radiologically defined ecological dynamics and clinical outcomes in glioblastoma multiforme: preliminary results. Transl Oncol (2014) 1.08
The Repurposing Drugs in Oncology (ReDO) Project. Ecancermedicalscience (2014) 1.08
Molecular heterogeneity in glioblastoma: potential clinical implications. Front Oncol (2015) 1.06
Genomic Determinants of PI3K Pathway Inhibitor Response in Cancer. Front Oncol (2012) 1.05
ABC transporters: unvalidated therapeutic targets in cancer and the CNS. Anticancer Agents Med Chem (2010) 1.05
Vesicular stomatitis virus has extensive oncolytic activity against human sarcomas: rare resistance is overcome by blocking interferon pathways. J Virol (2011) 1.04
Glioblastomas are composed of genetically divergent clones with distinct tumourigenic potential and variable stem cell-associated phenotypes. Acta Neuropathol (2013) 1.03
Dissecting cancer evolution at the macro-heterogeneity and micro-heterogeneity scale. Curr Opin Genet Dev (2014) 1.01
Size Does Matter: Why Polyploid Tumor Cells are Critical Drug Targets in the War on Cancer. Front Oncol (2014) 1.00
Parallel evolution under chemotherapy pressure in 29 breast cancer cell lines results in dissimilar mechanisms of resistance. PLoS One (2012) 0.99
Evolutionary triage governs fitness in driver and passenger mutations and suggests targeting never mutations. Nat Commun (2014) 0.97
The PI3K/AKT/mTOR pathway is a potential predictor of distinct invasive and migratory capacities in human ovarian cancer cell lines. Oncotarget (2015) 0.97
Dynamics of preventive vs post-diagnostic cancer control using low-impact measures. Elife (2015) 0.97
Zone-size nonuniformity of 18F-FDG PET regional textural features predicts survival in patients with oropharyngeal cancer. Eur J Nucl Med Mol Imaging (2014) 0.97
Inter and intratumour heterogeneity: a barrier to individualized medical therapy in renal cell carcinoma? Front Oncol (2012) 0.97
Mechanisms of resistance to photodynamic therapy. Curr Med Chem (2011) 0.96
A river model to map convergent cancer evolution and guide therapy in RCC. Nat Rev Urol (2015) 0.91
Hurdles in anticancer drug development from a regulatory perspective. Nat Rev Clin Oncol (2012) 0.90
Evolution of the predictive markers amphiregulin and epiregulin mRNAs during long-term cetuximab treatment of KRAS wild-type tumor cells. Invest New Drugs (2010) 0.89
Aromatase inhibition remodels the clonal architecture of estrogen-receptor-positive breast cancers. Nat Commun (2016) 0.88
In vitro models of tumor vessels and matrix: engineering approaches to investigate transport limitations and drug delivery in cancer. Adv Drug Deliv Rev (2013) 0.85
Intra-tumor heterogeneity: lessons from microbial evolution and clinical implications. Genome Med (2013) 0.84
Applying ecological and evolutionary theory to cancer: a long and winding road. Evol Appl (2012) 0.84
Tumour heterogeneity and immune-modulation. Curr Opin Pharmacol (2013) 0.84
Darwinian Dynamics of Intratumoral Heterogeneity: Not Solely Random Mutations but Also Variable Environmental Selection Forces. Cancer Res (2016) 0.84
Tumour Cell Heterogeneity. F1000Res (2016) 0.83
Revealing the inherent heterogeneity of human malignancies by variant consensus strategies coupled with cancer clonal analysis. BMC Bioinformatics (2014) 0.83
Adaptive Resistance to an Inhibitor of Chromosomal Instability in Human Cancer Cells. Cell Rep (2016) 0.82
The breast cancer genome--a key for better oncology. BMC Cancer (2011) 0.82
Histopathological determinants of tumor resistance: a special look to the immunohistochemical expression of carbonic anhydrase IX in human cancers. Curr Med Chem (2014) 0.82
Can we deconstruct cancer, one patient at a time? Trends Genet (2012) 0.81
Intraclonal diversity in follicular lymphoma analyzed by quantitative ultradeep sequencing of noncoding regions. J Immunol (2014) 0.81
Evolutionary strategy for systemic therapy of metastatic breast cancer: balancing response with suppression of resistance. Womens Health (Lond Engl) (2014) 0.81
A holistic view of cancer bioenergetics: mitochondrial function and respiration play fundamental roles in the development and progression of diverse tumors. Clin Transl Med (2016) 0.81
Ploidy-Seq: inferring mutational chronology by sequencing polyploid tumor subpopulations. Genome Med (2015) 0.81
Prediction of the number of activated genes in multiple independent Cd(+2)- and As(+3)-induced malignant transformations of human urothelial cells (UROtsa). PLoS One (2014) 0.81
Genetic and epigenetic heterogeneity of epithelial ovarian cancer and the clinical implications for molecular targeted therapy. J Cell Mol Med (2016) 0.81
Intra-Tumoral Heterogeneity of HER2, FGFR2, cMET and ATM in Gastric Cancer: Optimizing Personalized Healthcare through Innovative Pathological and Statistical Analysis. PLoS One (2015) 0.80
The value of monitoring to control evolving populations. Proc Natl Acad Sci U S A (2015) 0.80
JNK signaling is needed to tolerate chromosomal instability. Cell Cycle (2013) 0.80
Flow cytometry-assisted Monte Carlo simulation predicts clonogenic survival of cell populations with lognormal distributions of radiopharmaceuticals and anticancer drugs. Int J Radiat Biol (2011) 0.79
Genetic instability in the tumor microenvironment: a new look at an old neighbor. Mol Cancer (2015) 0.79
Ultradeep analysis of tumor heterogeneity in regions of somatic hypermutation. Genome Med (2015) 0.79
Tumor cell plasticity: the challenge to catch a moving target. J Gastroenterol (2014) 0.79
Chromosomal instability triggers cell death via local signalling through the innate immune receptor Toll. Oncotarget (2015) 0.78
Analysis and prediction of pathways in HeLa cells by integrating biological levels of organization with systems-biology approaches. PLoS One (2013) 0.78
An NGS Workflow Blueprint for DNA Sequencing Data and Its Application in Individualized Molecular Oncology. Cancer Inform (2016) 0.78
Using functional genomics to overcome therapeutic resistance in hematological malignancies. Immunol Res (2013) 0.78
Correlation of pretreatment (18)F-FDG PET tumor textural features with gene expression in pharyngeal cancer and implications for radiotherapy-based treatment outcomes. Eur J Nucl Med Mol Imaging (2016) 0.78
Capitalizing on Cancer Specific Replication: Oncolytic Viruses as a Versatile Platform for the Enhancement of Cancer Immunotherapy Strategies. Biomedicines (2016) 0.78
Differential clonal evolution in oesophageal cancers in response to neo-adjuvant chemotherapy. Nat Commun (2016) 0.78
A method to predict response of cell populations to cocktails of chemotherapeutics and radiopharmaceuticals: validation with daunomycin, doxorubicin, and the alpha particle emitter (210)Po. Nucl Med Biol (2012) 0.77
Stromal targeted therapy in bone metastatic prostate cancer: promise delivered. Asian J Androl (2011) 0.77
CGB and GNRH1 expression analysis as a method of tumor cells metastatic spread detection in patients with gynecological malignances. J Transl Med (2011) 0.77
Activation of Pim Kinases Is Sufficient to Promote Resistance to MET Small-Molecule Inhibitors. Cancer Res (2015) 0.77
Delivering preventive, predictive and personalised cancer medicine for renal cell carcinoma: the challenge of tumour heterogeneity. EPMA J (2011) 0.76
Androgen receptor and gene network: Micromechanics reassemble the signaling machinery of TMPRSS2-ERG positive prostate cancer cells. Cancer Cell Int (2014) 0.76
Autophagy regulates the survival of cells with chromosomal instability. Oncotarget (2016) 0.76
Chromosomal Instability Affects the Tumorigenicity of Glioblastoma Tumor-Initiating Cells. Cancer Discov (2016) 0.76
T Cell Adaptive Immunity Proceeds through Environment-Induced Adaptation from the Exposure of Cryptic Genetic Variation. Front Genet (2012) 0.76
The fibrotic microenvironment as a heterogeneity facet of hepatocellular carcinoma. Fibrogenesis Tissue Repair (2013) 0.76
Clonal dynamics following p53 loss of heterozygosity in Kras-driven cancers. Nat Commun (2016) 0.75
Clonal Evolutionary Analysis during HER2 Blockade in HER2-Positive Inflammatory Breast Cancer: A Phase II Open-Label Clinical Trial of Afatinib +/- Vinorelbine. PLoS Med (2016) 0.75
Detecting intratumoral heterogeneity of EGFR activity by liposome-based in vivo transfection of a fluorescent biosensor. Oncogene (2017) 0.75
Persistence to anti-cancer treatments in the stationary to proliferating transition. Cell Cycle (2016) 0.75
Targeting P-glycoprotein function, p53 and energy metabolism: Combination of metformin and 2-deoxyglucose reverses the multidrug resistance of MCF-7/Dox cells to doxorubicin. Oncotarget (2016) 0.75
A systematic approach to cancer: evolution beyond selection. Clin Transl Med (2017) 0.75
Context Specificity in Causal Signaling Networks Revealed by Phosphoprotein Profiling. Cell Syst (2016) 0.75
Renal cell cancer: what can we learn from pre-operative studies? Front Oncol (2011) 0.75
Tumour response in metastatic renal cell carcinoma treated with tyrosine kinase inhibitors - assessment of intra-tumour heterogeneity. BMC Med (2016) 0.75
Potential synergistic implications for stromal-targeted radiopharmaceuticals in bone-metastatic prostate cancer. Asian J Androl (2011) 0.75
Initiation of aberrant DNA methylation patterns and heterogeneity in precancerous lesions of human hepatocellular cancer. Epigenetics (2017) 0.75
Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med (2004) 71.08
Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med (2009) 24.75
The clonal evolution of tumor cell populations. Science (1976) 24.39
Genetic instabilities in human cancers. Nature (1998) 22.76
Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science (2001) 20.30
Multidrug resistance in cancer: role of ATP-dependent transporters. Nat Rev Cancer (2002) 15.72
Detection of mutations in EGFR in circulating lung-cancer cells. N Engl J Med (2008) 13.54
Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia. Cancer Cell (2002) 13.03
Cancer as an evolutionary and ecological process. Nat Rev Cancer (2006) 9.33
Genomic analysis of the clonal origins of relapsed acute lymphoblastic leukemia. Science (2008) 9.25
Mutator phenotype may be required for multistage carcinogenesis. Cancer Res (1991) 7.29
Subclonal phylogenetic structures in cancer revealed by ultra-deep sequencing. Proc Natl Acad Sci U S A (2008) 7.22
A signature of chromosomal instability inferred from gene expression profiles predicts clinical outcome in multiple human cancers. Nat Genet (2006) 7.16
A hypermutation phenotype and somatic MSH6 mutations in recurrent human malignant gliomas after alkylator chemotherapy. Cancer Res (2006) 6.91
Aneuploidy acts both oncogenically and as a tumor suppressor. Cancer Cell (2006) 6.37
Tumor heterogeneity: causes and consequences. Biochim Biophys Acta (2009) 5.90
Resistance to therapy caused by intragenic deletion in BRCA2. Nature (2008) 5.85
Presence of epidermal growth factor receptor gene T790M mutation as a minor clone in non-small cell lung cancer. Cancer Res (2006) 4.72
Analysis of epidermal growth factor receptor gene mutation in patients with non-small cell lung cancer and acquired resistance to gefitinib. Clin Cancer Res (2006) 4.62
Cytokine-dependent imatinib resistance in mouse BCR-ABL+, Arf-null lymphoblastic leukemia. Genes Dev (2007) 3.31
Adaptive therapy. Cancer Res (2009) 2.81
The mutation rate and cancer. Proc Natl Acad Sci U S A (1996) 2.73
Mad2-induced chromosome instability leads to lung tumour relapse after oncogene withdrawal. Nature (2010) 2.36
The genetics of breast cancer susceptibility. Annu Rev Genet (1998) 2.21
Phosphorylation of the ATP-binding loop directs oncogenicity of drug-resistant BCR-ABL mutants. Proc Natl Acad Sci U S A (2006) 2.13
Chromosomal instability determines taxane response. Proc Natl Acad Sci U S A (2009) 2.12
MSH6 mutations arise in glioblastomas during temozolomide therapy and mediate temozolomide resistance. Clin Cancer Res (2009) 2.11
Refractoriness to antivascular endothelial growth factor treatment: role of myeloid cells. Cancer Res (2008) 2.08
The genetic origin of drug resistance in neoplasms: implications for systemic therapy. Cancer Res (1984) 1.92
Circumventing resistance to kinase-inhibitor therapy. N Engl J Med (2006) 1.75
Cancer genome sequencing--an interim analysis. Cancer Res (2009) 1.52
Explaining the high mutation rates of cancer cells to drug and multidrug resistance by chromosome reassortments that are catalyzed by aneuploidy. Proc Natl Acad Sci U S A (2000) 1.36
Clonal origin of human tumors. Annu Rev Med (1979) 1.25
Evolutionary dynamics of mutator phenotypes in cancer: implications for chemotherapy. Cancer Res (2003) 1.10
Random mutations, selected mutations: A PIN opens the door to new genetic landscapes. Proc Natl Acad Sci U S A (2006) 1.01
Cancer heterogeneity: implications for targeted therapeutics. Br J Cancer (2013) 2.56
Utility of prognostic genomic tests in breast cancer practice: The IMPAKT 2012 Working Group Consensus Statement. Ann Oncol (2013) 1.41
Modulation of p27(Kip1) levels by the cyclin encoded by Kaposi's sarcoma-associated herpesvirus. EMBO J (1999) 1.30
Genomic analyses to select patients for adjuvant chemotherapy: trials and tribulations. Ann Oncol (2012) 0.95
Percutaneous endoscopic gastrostomy at the time of tumour resection in advanced oral cancer. Oral Oncol (2000) 0.83
A retrospective analysis of clinical outcome of patients with chemo-refractory metastatic breast cancer treated in a single institution phase I unit. Br J Cancer (2010) 0.76
Loss of BRCA1 or BRCA2 markedly increases the rate of base substitution mutagenesis and has distinct effects on genomic deletions. Oncogene (2017) 0.75
RAD18, WRNIP1 and ATMIN promote ATM signalling in response to replication stress. Oncogene (2016) 0.75
The amphetamines. Med J Aust (1967) 0.75
IFN-gamma down-regulates MHC expression and antigen processing in a human B cell line. J Immunol (1999) 0.75
Patupilone in patients with pretreated metastatic/locally recurrent colorectal cancer: results of the Phase II CINATRA trial. Invest New Drugs (2013) 0.75